Videos
Primary Myelofibrosis
CLL Case Review: IgHV-Unmutated Therapy Options
David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.
Andre Goy, MD, discusses a few combinations that are being investigated for the treatment of patients with relapsed/refractory mantle cell lymphoma.
High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
Polycythemia Vera
Silvia C. Formenti, MD, discusses the advantages of radiation therapy in patients with lung cancer compared to other modalities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
FDA Approves Expanded Automated PD-L1 Diagnostic Testing Across 4 Solid Tumor Types
3
Velzatinib Aims For Future Direct Comparison With Imatinib in GIST
4
Allostatic Load Emerges as a Risk Marker for Early-Onset Cancer
5